These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 19584690)

  • 1. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
    Bara C; Dengler T; Hack MA; Ladenburger S; Lehmkuhl HB
    Transplant Proc; 2013; 45(6):2387-92. PubMed ID: 23953553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M; Dengler T; Mattei MF; Poncelet A; Vanhaecke J; Vermes E; Kleinloog R; Li Y; Gezahegen Y; Delgado JF;
    Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
    Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
    J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.
    Eisen HJ; Kobashigawa J; Starling RC; Pauly DF; Kfoury A; Ross H; Wang SS; Cantin B; Van Bakel A; Ewald G; Hirt S; Lehmkuhl H; Keogh A; Rinaldi M; Potena L; Zuckermann A; Dong G; Cornu-Artis C; Lopez P
    Am J Transplant; 2013 May; 13(5):1203-16. PubMed ID: 23433101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
    Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
    Lorber MI; Mulgaonkar S; Butt KM; Elkhammas E; Mendez R; Rajagopalan PR; Kahan B; Sollinger H; Li Y; Cretin N; Tedesco H;
    Transplantation; 2005 Jul; 80(2):244-52. PubMed ID: 16041270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
    J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Mai D; Dandel M; Knosalla C; Hiemann NE; Grauhan O; Huebler M; Pasic M; Weng Y; Meyer R; Rothenburger M; Hummel M; Hetzer R
    J Heart Lung Transplant; 2007 Jul; 26(7):700-4. PubMed ID: 17613400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
    Bertoni E; Larti A; Rosso G; Zanazzi M; Di Maria L; Salvadori M
    J Nephrol; 2011; 24(5):613-8. PubMed ID: 21240873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation.
    Zuckermann A; Arizon JM; Dong G; Eisen HJ; Kobashigawa J; Lehmkuhl H; Ross H; Pelligrini C; Wang SS; Barten MJ
    Transplantation; 2011 Sep; 92(5):594-600. PubMed ID: 21862955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
    Albano L; Alamartine E; Toupance O; Moulin B; Merville P; Rerolle JP; Tetaz R; Moal MC; Kamar N; Legendre C; Quéré S; Di Giambattista F; Terpereau A; Dantal J
    Ann Transplant; 2012; 17(1):58-67. PubMed ID: 22466910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.
    Vítko S; Margreiter R; Weimar W; Dantal J; Kuypers D; Winkler M; Øyen O; Viljoen HG; Filiptsev P; Sadek S; Li Y; Cretin N; Budde K;
    Am J Transplant; 2005 Oct; 5(10):2521-30. PubMed ID: 16162203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen.
    Schnuelle P; van der Heide JH; Tegzess A; Verburgh CA; Paul LC; van der Woude FJ; de Fijter JW
    J Am Soc Nephrol; 2002 Feb; 13(2):536-543. PubMed ID: 11805185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.